Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3200882 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
LY3200882 + pembrolizumab is an investigational combination therapy for advanced cancers. LY3200882 is a next-generation, potent, selective small molecule inhibitor of transforming growth factor beta (TGFβ) receptor type-1 (TGFβR1) that blocks TGFβ signaling, acting as an ATP-competitive serine-threonine kinase inhibitor. Pembrolizumab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), blocking its interaction with ligands PD-L1 and PD-L2, thus restoring anti-tumor T-cell immunity. This combination is being studied for synergistic immunomodulatory and anti-tumor effects in metastatic or advanced cancers[1][5].
- Other names
- LY3200882 + Keytruda
02
Targets
TGFBR1PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on LY3200882 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3200882 + pembrolizumab.